Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
- 10 January 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2) , 130-138
Abstract
Purpose: Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake. Methods: We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and 2014. Our primary analysis used modified Poisson regression to determine the association between race and whether ODX testing was ordered among two strata: node-negative and node-positive breast cancer. Results: A total of 1,468 women with estrogen receptor–positive, human epidermal growth factor receptor-2–negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than non-black women. Overall, 42% of women had ODX test results in their pathology reports. Compared with those who did not receive ODX testing, women who received ODX testing tended to be younger and have medium tumor size and grade. Our regression analyses indicated no racial disparities in ODX uptake among node-negative patients. However, racial differences were detected among node-positive patients, with black patients being 46% less likely to receive ODX testing than non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006). Conclusion: We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non–guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.Keywords
This publication has 35 references indexed in Scilit:
- Oncotype Dx Results in Multiple Primary Breast CancersBreast Cancer: Basic and Clinical Research, 2014
- Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast CancerJournal of Clinical Oncology, 2012
- Factors Influencing Treatment Recommendations in Node-Negative Breast CancerJournal of Oncology Practice, 2011
- Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene AssayJournal of Oncology Practice, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology GroupJNCI: Journal of the National Cancer Institute, 2009
- Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic FeaturesJournal of Clinical Oncology, 2008
- Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancerCancer, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapyEuropean Journal of Cancer, 1995